Denali Therapeutics (DNLI) Non Operating Income (2017 - 2023)

Denali Therapeutics (DNLI) has 7 years of Non Operating Income data on file, last reported at $13.1 million in Q4 2023.

• Non Operating Income for Q4 2023 came in at $13.1 million, up 97.13% year-over-year; the trailing twelve-month figure through Dec 2023 was $51.5 million (up 248.62% YoY), and the FY2023 annual result was $51.5 million, up 248.62% from the prior year.
• Non Operating Income fell to $13.1 million in Q4 2023 per DNLI's latest filing, from $14.4 million in the prior quarter.
• Over five years, Non Operating Income peaked at $14.4 million in Q3 2023 and troughed at $1.0 million in Q3 2021.
• A 5-year average of $4.8 million and a median of $3.1 million in 2020 frame the typical range for Non Operating Income.
• The sharpest annual moves came in 2021 and 2023: Non Operating Income slumped 61.58% in 2021, then jumped 763.38% in 2023.
• A 5-year view of Non Operating Income shows it stood at $3.8 million in 2019, then slumped by 56.9% to $1.6 million in 2020, then fell by 21.17% to $1.3 million in 2021, then soared by 418.29% to $6.7 million in 2022, then soared by 97.13% to $13.1 million in 2023.
• Business Quant data shows DNLI's Non Operating Income at $13.1 million in Q4 2023, $14.4 million in Q3 2023, and $12.9 million in Q2 2023.